A61K 31/131
Acyclic
Official title: acyclic
A61K31/131 (Acyclic) appears on 257 US grants and 358 published applications in this corpus.
Search patents in A61K- Granted patents
- 257
- Published applications
- 358
- Assignees
- 231
- Inventors
- 639
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 5 | 0 |
| 1996 | 8 | 0 |
| 1997 | 12 | 0 |
| 1998 | 10 | 0 |
| 1999 | 14 | 0 |
| 2000 | 7 | 0 |
| 2001 | 11 | 3 |
| 2002 | 10 | 11 |
| 2003 | 11 | 17 |
| 2004 | 4 | 13 |
| 2005 | 3 | 10 |
| 2006 | 7 | 6 |
| 2007 | 2 | 9 |
| 2008 | 3 | 9 |
| 2009 | 1 | 10 |
| 2010 | 3 | 15 |
| 2011 | 4 | 12 |
| 2012 | 9 | 15 |
| 2013 | 10 | 16 |
| 2014 | 9 | 26 |
| 2015 | 8 | 16 |
| 2016 | 13 | 16 |
| 2017 | 8 | 19 |
| 2018 | 10 | 16 |
| 2019 | 13 | 17 |
| 2020 | 11 | 18 |
| 2021 | 8 | 20 |
| 2022 | 10 | 20 |
| 2023 | 12 | 13 |
| 2024 | 7 | 12 |
| 2025 | 6 | 10 |
| 2026 | 6 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treating triple-negative breast cancer25 Aug 2026US 12,714,691 B2Dana-Farber Cancer Institute, Inc.
- Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition16 Jun 2026US 12,653,809 B2Nurix Therapeutics, Inc.
- Compositions and methods for treating cancer with atypical BRAF mutations24 Mar 2026US 12,582,635 B2Biomed Valley Discoveries, Inc.
- Selective serotonin receptor modulators and methods of making and using the same10 Mar 2026US 12,570,602 B2Park City Bio, LLC
- Selective serotonin receptor modulators and methods of making and using the same3 Mar 2026US 12,564,560 B1Park City Bio, LLC
- Selective Serotonin Receptor Modulators and Methods of Making and Using the Same27 Aug 2026US 2026/0250237 A1Park City Bio, LLC
- Structured molecular vectors for anti-inflammatory compounds and uses thereof13 Aug 2026US 2026/0234173 A1Centre National De La Recherche Scientifique
- Use of 5-methoxy-2-aminoindan ("meai") in methods for treating metabolic syndrome6 Aug 2026US 2026/0224512 A1Clearmind Labs Corp.
- Oral product6 Aug 2026US 2026/0224580 A1Nicoventures Trading Limited
- Selective Serotonin Receptor Modulators and Methods of Making and Using the Same30 Jul 2026US 2026/0216101 A1Park City Bio, LLC
Most cited
By later US patents
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Methods and devices for treating plumonary vasoconstriction and asthma251US 5,485,827 AThe General Hospital Corporation · 1996
- Therapeutic inhibitor of vascular smooth muscle cells245US 6,171,609 B2NeoRx Corporation · 2001
- Therapeutic inhibitor of vascular smooth muscle cells179US 6,306,421 B1NeoRx Corporation · 2001
- Therapeutic inhibitor of vascular smooth muscle cells171US 6,515,009 B1NeoRx Corporation · 2003